MOLOGEN AG presented two posters on the cancer immunotherapy MGN1703 at the Gastrointestinal Cancers Symposium 2015 in San Francisco, California. The first poster featured promising data on overall survival of patient subgroups from the IMPACT study in colorectal cancer. The data suggests that responders to induction therapy may benefit the most from a switch maintenance treatment with MGN1703.

This is reflected in the pivotal study IMPALA where 'response to induction therapy' is one of the main inclusion criteria. The second poster outlined the design of the IMPALA trial, which has been already started in 2014 and is currently enrolling patients. Further to the IMPALA trial in colorectal cancer, MGN1703 is being investigated for first-line maintenance treatment of extensive-stage small cell lung cancer, a serious cancer disease with high unmet medical need.

IMPULSE, an international randomized controlled trial, is currently enrolling patients as well.